Micro Labs is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $22.8B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Micro Labs's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Eliquis | Bristol Myers Squibb / Pfizer | Generic | 2028 | FDA-approved, Dec 2019 | $14.4B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Micro Labs's share of it.